Concepedia

Mark R. Witmer

MR

27

Publications

1.5K

Citations

22

H-Index

1989

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Bristol-Myers Squibb (Sweden)

Princeton University

Biocon (India)

Mark R. Witmer is an author at Bristol-Myers Squibb (United States) specializing in biochemistry, natural sciences, and medicine.

ORCID

Top concepts

Publications per year

1989–2017

27

Publications

27

Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

Steve Poirier, Gaétan Mayer, Viviane Poupon et al. · Journal of Biological Chemistry · 2009 · 265 citations · Full text

Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering

Tracy Mitchell, Ginger Chao, Doree Sitkoff et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 128 citations

Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain

John S. Tokarski, Adriana Zupa-Fernandez, Jeffrey Tredup et al. · Journal of Biological Chemistry · 2015 · 112 citations · Full text

2-Aryl-2,2-difluoroacetamide FKBP12 Ligands:  Synthesis and X-ray Structural Studies

Gene M. Dubowchik, Vivekananda M. Vrudhula, Bireshwar Dasgupta et al. · Organic Letters · 2001 · 103 citations

, , +15

Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase

Robert G. Gentles, Min Ding, John A. Bender et al. · Journal of Medicinal Chemistry · 2014 · 98 citations · Full text

Rows per page

1–5 of 27